Togontech
Accelerating human antibody discovery and development.
Vision
Antibodies play a crucial role in protecting us against infectious diseases. They can neutralize pathogens and help the immune system eliminate them.
Given their protective function, antibodies are increasingly used in therapies to treat infections, especially when vaccines or antibiotics are not effective. Their specificity and adaptability make them powerful tools in modern medicine.
A remarkable example of antibody-based therapy occurred in 1925 when sled dog Togo played a critical role in delivering diphtheria antitoxin to Nome, Alaska. The serum run, also known as the "Great Race of Mercy," involved teams of sled dogs transporting life-saving diphtheria antitoxin across more than 1,000 kilometers of harsh terrain. Their mission saved numerous lives and became a legendary symbol of determination and scientific achievement.
Today, Togontech builds on this legacy by identifying and developing next-generation antibodies. The company is focused on advancing novel antibody candidates and translating them into effective treatments for patients. By combining cutting-edge biotechnology with a deep commitment to global health, Togontech aims to effectively provide antibody-based therapies in the fight against infectious diseases.
Togo, the lead sled dog during the 1925 serum run, braved the most difficult and dangerous stretches of the journey. His endurance and intelligence were instrumental in the success of the endeavor, embodying the spirit that inspires Togontech’s mission today.
Team Expertise
10+ patent applications, 4 antibodies licensed
50+ years of combined expertise in antibody research, targeting infectious pathogens
100+ in vivo experiments conducted, including humanized mice
4,000+ monoclonal antibodies isolated and characterized
500,000+ neutralization assays performed
Principal investigators of observational and interventional clinical studies
News
2025 – Togontech and University of Cologne establish cooperation agreement for biosafety and animal facilities.
2025 – Togontech opens new laboratory facilities in Cologne, Germany
October 2024 – Togontech established partnership with Vir Biotechnology to advance pre-clinical development of broadly neutralizing anti-HIV antibody candidates
May 2024 – Togontech was founded with the purpose of accelerating human antibody discovery and development